- Recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
This study looks at how men with advanced prostate cancer respond to darolutamide and hormone therapy, sometimes with chemotherapy, in real-world settings. It aims to understand treatment effectiveness, safety, and patient experiences to help improve care.
For: Metastatic Hormone-Sensitive Prostate CancerBelgium · Finland · France - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
For: Prostatic NeoplasmsUnited States · Austria · Belgium - RecruitingPHASE3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
This study compares a new, shorter radiation treatment for prostate cancer with the usual treatment. It checks if the new method, using high-dose radiation in fewer sessions, works as well as the standard approach which combines external radiation with tiny radioactive seeds placed inside the prostate.
For: Prostate CancerUnited States · Canada - Active not recruitingPHASE2, PHASE3
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
This study, called STAMPEDE, looks for better ways to treat prostate cancer that is spreading or has a high chance of spreading. It tests new treatments against standard ones to help men live longer and have a better quality of life.
For: Prostate CancerSwitzerland · United Kingdom - Active not recruitingPHASE3
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
This study looks at a new way to treat prostate cancer that has come back. It combines a drug called darolutamide with standard hormone therapy, aiming to stop the cancer from spreading. Researchers want to see if this combination helps men live longer without their cancer getting worse.
For: Biochemically Recurrent Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE2
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
This study compares a new drug, ODM-201, with standard hormone therapy (ADT) for men with prostate cancer. We want to see if ODM-201 can lower a specific blood marker (PSA) just as well as ADT, with potentially fewer side effects.
For: Prostate CancerBelgium · France · Italy - Active not recruitingPHASE2
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
This study looks into a new treatment (AAA617) for a type of prostate cancer that has stopped responding to standard hormone therapy. It also checks if combining AAA617 with existing hormone-blocking drugs works better.
For: Prostatic NeoplasmUnited States · Brazil · Canada